Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy Meeting Abstract

  

Authors:	Shah, N. J.; Campbell, M. T.; Mao, S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H.; Keshava-Prasad, H.; Hoimes, C. J.; Hussain, A.; George, S.; Gourdin, T. S.; Nelson, A.; Yan, H.; Esquibel, V.; McIntyre, G.; Geller, R.; Voss, M. H.; Rini, B. I.; Beckermann, K.
Abstract Title:	Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
Meeting Title:	ESMO Congress 2023
Journal Title:	Annals of Oncology
Volume:	34
Issue:	Suppl. 2
Meeting Dates:	2023 Oct 20-24
Meeting Location:	Madrid, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2023-10-01
Start Page:	S1016
End Page:	S1017
Language:	English
ACCESSION:	WOS:001087480202554
DOI:	10.1016/j.annonc.2023.09.1119
PROVIDER:	wos
Notes:	Meeting Abstract: 1889P -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/212831